HomeCompareCDBT vs PFE

CDBT vs PFE: Dividend Comparison 2026

CDBT yields 2000.00% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CDBT wins by $9939315158.48M in total portfolio value
10 years
CDBT
CDBT
● Live price
2000.00%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9939315158.53M
Annual income
$9,049,252,674,478,578.00
Full CDBT calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — CDBT vs PFE

📍 CDBT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCDBTPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CDBT + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CDBT pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CDBT
Annual income on $10K today (after 15% tax)
$170,000.00/yr
After 10yr DRIP, annual income (after tax)
$7,691,864,773,306,791.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, CDBT beats the other by $7,691,864,773,283,662.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CDBT + PFE for your $10,000?

CDBT: 50%PFE: 50%
100% PFE50/50100% CDBT
Portfolio after 10yr
$4969657579.29M
Annual income
$4,524,626,337,252,894.00/yr
Blended yield
91.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CDBT
No analyst data
Altman Z
-9.4
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CDBT buys
0
PFE buys
0
No recent congressional trades found for CDBT or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCDBTPFE
Forward yield2000.00%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$9939315158.53M$51.1K
Annual income after 10y$9,049,252,674,478,578.00$27,210.54
Total dividends collected$9876141646.27M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CDBT vs PFE ($10,000, DRIP)

YearCDBT PortfolioCDBT Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$210,700$200,000.00$9,161$701.38+$201.5KCDBT
2$4,163,767$3,938,317.76$8,610$859.79+$4.16MCDBT
3$77,191,133$72,735,902.82$8,366$1,081.25+$77.18MCDBT
4$1,342,813,676$1,260,219,163.76$8,483$1,405.66+$1342.81MCDBT
5$21,925,333,121$20,488,522,486.99$9,084$1,907.24+$21925.32MCDBT
6$336,109,296,351$312,649,189,912.21$10,418$2,732.78+$336109.29MCDBT
7$4,838,913,266,619$4,479,276,319,522.88$13,007$4,193.56+$4838913.25MCDBT
8$65,446,276,951,058$60,268,639,755,775.59$18,010$7,005.87+$65446276.93MCDBT
9$831,834,097,245,644$761,806,580,908,011.90$28,216$12,979.89+$831834097.22MCDBT
10$9,939,315,158,531,418$9,049,252,674,478,578.00$51,081$27,210.54+$9939315158.48MCDBT

CDBT vs PFE: Complete Analysis 2026

CDBTStock

China Dasheng Biotechnology Company, together with its subsidiaries, engages in the production, marketing, and distribution of bacteria based products used as additives for livestock feed and crop cultivation in the People's Republic of China. It provides artificial microorganisms (AM) and high-efficiency microorganism (HM) based biological bacterium blends; and biological preservatives. The company offers AM/HM bacteria based additives for crops, including Bulgaria lactobacillus, beer microzyme, and dark red spirilla used to increase the beneficial microorganism colonies in soil; inhibit the reproduction of harmful fungi and putrefactive bacteria; and to improve nutrient absorption and reduce crop and livestock diseases. It also provides AM/HM bacteria based additives for livestock feed, which softens the livestock feed and restrain the growth and reproduction of pathogenic bacteria, as well as supplies beneficial nutriments, including organic acid, vitamins, enzyme, antibiotics, mycelium protein, and other growth-enhancing substances that balance the nutrients in the feed. In addition, the company offers FGW bacterial based preservatives that preserve animal specimens for scientific research; and preserve the freshness for agricultural produce. Further, it provides bacteria based fertilizer for application on plants, such as vegetable and fruit leaves. Additionally, China Dasheng Biotechnology Company engages in residential and commercial real estate investment. The company was formerly known as Max Nutrition, Inc. and changed its name to China Dasheng Biotechnology Company in March 2008. China Dasheng Biotechnology Company is based in Lanzhou, China.

Full CDBT Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CDBT vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CDBT vs SCHDCDBT vs JEPICDBT vs OCDBT vs KOCDBT vs MAINCDBT vs JNJCDBT vs MRKCDBT vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.